Media & Resources

North American and African clinical trials led by Scripps Research, IAVI and additional collaborators across the U.S. and Africa mark progress toward an effective HIV vaccine.

MTBVAC caused similar or stronger immune responses compared to the Bacille Calmette-Guérin (BCG) vaccine.

MTBVAC is a promising vaccine candidate being evaluated in the IMAGINE trial for the prevention of TB disease in adolescents and adults with latent TB infection in South Africa, Kenya, and Tanzania.

The vaccine candidate is being evaluated in a ring vaccination trial as part of a comprehensive public health response.

The two partners will harness their complementary strengths to advance their shared mission of creating an innovative, end-to-end model for sustainable vaccine access in Africa.

Partnership also to include efforts to strengthen the continent's disease-fighting capacity, pandemic readiness, and supply resilience.

Across four preclinical studies, Scripps Research, IAVI, and additional collaborators make headway in stimulating the rare antibodies needed to fight HIV.

The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI’s single dose Lassa fever vaccine candidate.